{"id":13116,"date":"2025-08-21T04:35:13","date_gmt":"2025-08-21T04:35:13","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/13116\/"},"modified":"2025-08-21T04:35:13","modified_gmt":"2025-08-21T04:35:13","slug":"gilead-sciences-ceo-says-hiv-prevention-drug-offers-clear-value","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/13116\/","title":{"rendered":"Gilead Sciences CEO Says HIV Prevention Drug Offers Clear Value"},"content":{"rendered":"<p class=\"media-ui-Paragraph_text-SqIsdNjh0t0-\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/GILD:US\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Gilead Sciences Inc.<\/a> Chief Executive Officer Daniel O\u2019Day said the company\u2019s new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump administration will handle recommendations for treatments like this.  <\/p>\n<p class=\"media-ui-Paragraph_text-SqIsdNjh0t0-\" data-component=\"paragraph\">\u201cIt\u2019s a very straightforward economic argument to prevent the disease,\u201d O\u2019Day said in an interview at Bloomberg\u2019s headquarters in New York Friday. \u201cNo one wants HIV to continue to expand in this country.\u201d <\/p>\n","protected":false},"excerpt":{"rendered":"Gilead Sciences Inc. Chief Executive Officer Daniel O\u2019Day said the company\u2019s new HIV prevention drug Yeztugo should be&hellip;\n","protected":false},"author":2,"featured_media":13117,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[12008,12317,12316,718,18,6945,135,475,474,19,11995,17,11867,4164,968,12318,211],"class_list":{"0":"post-13116","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-chief-executive-officer","9":"tag-clear-value-sas","10":"tag-daniel-daniel","11":"tag-drugs","12":"tag-eire","13":"tag-gilead-sciences-inc","14":"tag-health","15":"tag-health-care","16":"tag-healthcare","17":"tag-ie","18":"tag-industries","19":"tag-ireland","20":"tag-july-sarl-caen","21":"tag-law","22":"tag-new-york","23":"tag-policy","24":"tag-wall-street"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/13116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=13116"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/13116\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/13117"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=13116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=13116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=13116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}